The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5α-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement
Open accessAbstract
CONTEXT: Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane] is the first-line treatment for metastatic adrenocortical carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumor. Mitotane is considered an adrenolytic substance, but there is limited information on distinct effects on steroidogenesis. However, adrenal insufficiency and male hypogonadism are widely recognized side effects of mitotane treatment. OBJECTIVE: Our objective was to define the impact of mitotane treatment on in vivo steroidogenesis in patients with ACC. SETTING AND DESIGN: At seven European specialist referral centers for adrenal tumors, we analyzed 24-h urine samples (n = 127) collected from patients with ACC before and during mitotane therapy in the adjuvant setting (n = 23) or for metastatic ACC (n = 104). Urinary steroid metabolite excretion was profiled by gas chromatography/mass spectrometry in comparison with healthy controls (n = 88). RESULTS: We found a sharp increase in the excretion of 6β-hydroxycortisol over cortisol (P < 0.001), indicative of a strong induction of the major drug-metabolizing enzyme cytochrome P450 3A4. The contribution of 6β-hydroxycortisol to total glucocorticoid metabolites increased from 2% (median, interquartile range 1-4%) to 56% (39-71%) during mitotane treatment. Furthermore, we documented strong inhibition of systemic 5α-reductase activity, indicated by a significant decrease in 5α-reduced steroids, including 5α-tetrahydrocortisol, 5α-tetrahydrocorticosterone, and androsterone (all P < 0.001). The degree of inhibition was similar to that in patients with inactivating 5α-reductase type 2 mutations (n = 23) and patients receiving finasteride (n = 5), but cluster analysis of steroid data revealed a pattern of inhibition distinct from these two groups. Longitudinal data showed rapid onset and long-lasting duration of the observed effects. CONCLUSIONS: Cytochrome P450 3A4 induction by mitotane results in rapid inactivation of more than 50% of administered hydrocortisone, explaining the need for doubling hydrocortisone replacement in mitotane-treated patients. Strong inhibition of 5α-reductase activity is in line with the clinical observation of relative inefficiency of testosterone replacement in mitotane-treated men, calling for replacement by 5α-reduced androgens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medications that induce the drug-metabolizing enzyme CYP3A4 (eg, carbamazepine, mitotane, St John's wort) also increase cortisol clearance, necessitating a higher replacement dose (131).”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has recently become clear that mitotane is a very strong inducer of the drug-metabolizing microsomal liver and gut enzyme CYP3A4 (299, 301–303).”
From Adrenocortical carcinoma (2014) · cites this paper as [299]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, urine steroid metabolome analysis revealed that mitotane strongly inhibits 5α-reductase activity in ACC patients, explaining treatment-related male hypogonadism, and acts as a strong inducer of CYP3A4, resulting in significantly accelerated cortisol inactivation.”
From Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism (2019) · cites this paper as [191]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Drugs inducing the enzyme CYP3A4 may also affect the metabolism of cortisol, resulting in its faster inactivation to 6β-hydroxycortisol, hence, a need for an increased dose of exogenous GCs per day [16].”
From Glucocorticoid withdrawal-an overview on when and how to diagnose adrenal insufficiency in clinical practice (2021) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The latter explains the need for increased doses of glucocorticoid replacement therapy in patients with ACC receiving mitotane treatment (191).”
From Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism (2019) · cites this paper as [191]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2012) · Encyclopedia of the Sciences of Learning · doi:10.1007/978-1-4419-1428-6_5195 · Cited by 19,370
Russell, E. L., Chiang, L. H., & Braatz, R. D. (2000) · Advances in Industrial Control · doi:10.1007/978-1-4471-0409-4_3 · Cited by 7,862
Pattern Classification (2nd ed.)
Duda, R. O., Hart, P. E., & Stork, D. G. (1999) · Cited by 2,520
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade-Brittinger, C., Lacroix, A., Jarzab, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 873
Self-citationAdjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Fassnacht, M., Daffara, F., Tauchmanova, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 764
Self-citationLuton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717
Self-citationUrine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors
Arlt, W., Biehl, M., Taylor, A. E., Hahner, S., Libé, R., Hughes, B. A., Schneider, P., Smith, D. J., Stiekema, H., Krone, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1565 · Cited by 458
Self-citationWaxman, D. J., Attisano, C., Guengerich, F. P., & Lapenson, D. P. (1988) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(88)90655-8 · Cited by 414
Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).
Wrighton, S. A., Brian, W. R., Sari, M. A., Iwasaki, M., Guengerich, F. P., Raucy, J. L., Molowa, D. T., & Vandenbranden, M. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09441-6 · Cited by 402
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396 · cited 2×
“Adrenocortical carcinoma (ACC) is a rare cancer, with an incidence of one to two cases per million per year and a poor prognosis, mostly due to a high risk of recurrence and limited therapeutic options (1).”
BackgroundSelf-citationGed, C., Rouillon, J., Pichard, L., Combalbert, J., Bressot, N., Bories, P., Michel, H., Beaune, P., & Maurel, P. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb03516.x · Cited by 333
Hutter, A. M., & Kayhoe, D. E. (1966) · The American Journal of Medicine · doi:10.1016/0002-9343(66)90220-8 · Cited by 271
Mitotane Use in Inoperable Adrenal Cortical Carcinoma
Lubitz, J. A. (1973) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1973.03220100011003 · Cited by 224
Treatment of Cushing's Disease by o,p′DDD: Survey of 62 Cases
Luton, J. P., Mahoudeau, J. A., Bouchard, P., Thieblot, P., Hautecouverture, M., Simon, D., Laudat, M. H., Touitou, Y., & Bricaire, H. (1979) · New England Journal of Medicine · doi:10.1056/nejm197903013000903 · Cited by 210
Epstein, A. L., Levy, R., Kim, H., Henle, W., Henle, G., & Kaplan, H. S. (1978) · Cancer · doi:10.1002/1097-0142(197811)42:5<2379::aid-cncr2820420539>3.0.co;2-4 · Cited by 180
Hermsen, I. G., Fassnacht, M., Terzolo, M., Houterman, S., den Hartigh, J., Leboulleux, S., Daffara, F., Berruti, A., Chadarevian, R., Schlumberger, M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2676 · Cited by 173
Self-citationProspective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly
Daffara, F., De Francia, S., Reimondo, G., Zaggia, B., Aroasio, E., Porpiglia, F., Volante, M., Termine, A., Di Carlo, F., Dogliotti, L., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0103 · Cited by 167
Self-citationGalteau, M. M., & Shamsa, F. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0690-3 · Cited by 166
Mitotane for adrenocortical carcinoma treatment.
Hahner, S., & Faßnacht, M. (2005) · PubMed · Cited by 156
Self-citationKroiss, M., Quinkler, M., Lutz, W. K., Allolio, B., & Fassnacht, M. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04214.x · Cited by 148
Self-citationMitotane has a strong and a durable inducing effect on CYP3A4 activity
van Erp, N. P., Guchelaar, H.-J., Ploeger, B. A., Romijn, J. A., Hartigh, J. D., & Gelderblom, H. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0956 · Cited by 118
An Effect of o,p′-DDD on the Extra-adrenal Metabolism of Cortisol in Man
Bledsoe, T. J., Island, D. P., Ney, R. L., & Liddle, G. W. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-12-1303 · Cited by 111
Nader, N., Raverot, G., Emptoz-Bonneton, A., Déchaud, H., Bonnay, M., Baudin, E., & Pugeat, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2157 · Cited by 89
Effect of o,p'DDD on Human Adrenal Steroid llβ-Hydroxylation Activity
Brown, R. D., Nicholson, W. E., CHICK, W. T., & Strott, C. A. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-36-4-730 · Cited by 81
EFFECTS OF o,p' DDD1ON HISTOLOGY AND 17- HYDROXYCORTICOSTEROID OUTPUT OF THE DOG ADRENAL CORTEX1
Vilar, O., & Tullner, W. W. (1959) · Endocrinology · doi:10.1210/endo-65-1-80 · Cited by 77
Hogan, T. F., Citrin, D. L., Johnson, B. M., Nakamura, S., Davis, T. E., & Borden, E. C. (1978) · Cancer · Cited by 72
Treatment of Cushing's Disease
Temple, T. E., Jones, D. J., Liddle, G. W., & Dexter, R. N. (1969) · New England Journal of Medicine · doi:10.1056/nejm196910092811501 · Cited by 71
THE EFFECT OF o,p'‐DDD ON ADRENAL STEROID REPLACEMENT THERAPY REQUIREMENTS
Robinson, B. G., HALES, I. B., Henniker, A. J., Ho, K. K. Y., Luttrell, B. M., SMEE, I. R., & Stiel, J. N. (1987) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1987.tb01171.x · Cited by 63
Ultrastructure of Adrenal Cortex of the Dog During Treatment With DDD 2 , 3
KAMINSKY, N., LUSE, S., & Hartroft, P. M. (1962) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/29.1.127 · Cited by 54
The effect of o,p′ DDD on cortisol and hexobarbital metabolism
Kupfer, D., & Peets, L. (1966) · Biochemical Pharmacology · doi:10.1016/0006-2952(66)90024-4 · Cited by 51
Hague, R. V., MAY, W., & Cullen, D. R. (1989) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1989.tb00453.x · Cited by 49
Possible Mechanism and Treatment of o,p' DDD-induced Hypercholesterolaemia
MAHER, V., Trainer, P. J., Scoppola, A., Anderson, J. V., Thompson, G., & BESSER, G. M. (1992) · QJM · doi:10.1093/oxfordjournals.qjmed.a068705 · Cited by 48
Regression of Adrenal Cancer and Suppression of Adrenal Function in Man by o,p′-DDD
Bergenstal, D. M., LIPSETT, M. B., MOY, R. H., & Hertz, R. (1960) · Elsevier eBooks · doi:10.1016/b978-1-4832-2866-2.50035-0 · Cited by 48
Remission in Cushing's Syndrome with o,p′-DDD1
Southren, A. L., Tochimoto, S., Strom, L., RATUSCHNI, A., Ross, H., & Gordon, G. G. (1966) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-26-3-268 · Cited by 46
The Effect of Dexamethasone on the Pharmacokinetics of Triazolam
Villikka, K., Kivistö, K. T., & Neuvonen, P. J. (1998) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1998.tb01457.x · Cited by 45
6βHydroxy cortisol: A Noninvasive Indicator of Enzyme Induction*
Saenger, P. H., Förster, E., & Kream, J. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-52-3-381 · Cited by 45
Donadille, B., Groussin, L., Waintrop, C., Abbas, H., Tenenbaum, F., Dugué, M.-A., Coste, J., BERTAGNA, X. Y., & Bertherat, J. Y. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1317 · Cited by 41
Self-citationStimulation by o,p′-DDD of cortisol metabolism in the guinea pig
Kupfer, D., Balázs, T., & Buyske, D. A. (1964) · Life Sciences · doi:10.1016/0024-3205(64)90105-5 · Cited by 38
Metastatic adrenal cortical carcinoma. Prolonged regression with mitotane therapy
Jarabak, J. (1981) · JAMA · doi:10.1001/jama.246.15.1706 · Cited by 30
A Peripheral Action of o,p′-DDD on Steroid Biotransformation
Bradlow, H. L., Fukushima, D. K., Zumoff, B., et al. (1963) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-23-9-918 · Cited by 29
Effect of o,p'-DDD on Hepatic Metabolism of Pentobarbital in Rats,
Straw, J. A., Waters, I. W., & Fregly, M. J. (1965) · Experimental Biology and Medicine · doi:10.3181/00379727-118-29853 · Cited by 28
Jensen, B. L. (1987) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(87)90078-0 · Cited by 26
Primary Hypogonadism Associated with O,P′ DDD (mitotane) Therapy
Sparagana, M. (1987) · Journal of Toxicology Clinical Toxicology · doi:10.3109/15563658708992649 · Cited by 22
Stimulation of rat liver 3-hydroxy-3-methylglutaryl-coenzyme a reductase activity by o,p′-DDD
Stacpoole, P. W., Varnado, C. E., & Island, D. P. (1982) · Biochemical Pharmacology · doi:10.1016/0006-2952(82)90474-9 · Cited by 17
Touitou, Y., Bogdan, A., Auzéby, A., et al. (1979) · Journal of Endocrinology · doi:10.1677/joe.0.0820087 · Cited by 14
Kurokohchi, K., Nishioka, M., & Ichikawa, Y. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90131-2 · Cited by 11
The Effects of o,p′-DDD on Adrenal Steroidogenesis and Hepatic Steroid Metabolism
Ojima, M., SAITOH, M., Itoh, N., et al. (1985) · Folia Endocrinologica Japonica · doi:10.1507/endocrine1927.61.3_168 · Cited by 11
Wooten (1993) · doi:10.1002/1097-0142(19931201)72:11<3145::aid-cncr2820721105>3.0.co;2-n
Research works printed but not linked: 1
- Allolio, 1985, Comparison between hydrocortisone and cortisone acetate as replacement therapy in adrenocortical insufficiency., Aktuelle Endokrinologie Stoffwechsel, 6, 35
Cited by
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
Self-citationTreatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Self-citationElse, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Diagnosis and management of adrenal insufficiency
Bancos, I., Hahner, S., Tomlinson, J., & Arlt, W. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70142-1 · Cited by 467
Self-citation
Metadata
- Authors
- Chortis, V., Taylor, A. E., Schneider, P., Tomlinson, J. W., Hughes, B. A., O'Neil, D. M., Libé, R., Allolio, B., Bertagna, X., Bertherat, J., Beuschlein, F., Fassnacht, M., Karavitaki, N., Mannelli, M., Mantero, F., Opocher, G., Porfiri, E., Quinkler, M., Sherlock, M., Terzolo, M., Nightingale, P., Shackleton, C. H. L., Stewart, P. M., Hahner, S., & Arlt, W.
- Affiliations
- University of Birmingham (GB)
- Centre for Endocrinology, Diabetes, and Metabolism (V.C., A.E.T., P.S., J.W.T., B.A.H., D.M.O'N., M.S., C.H.L.S., P.M.S., W.A.), Birmingham B15 2TT, United Kingdom
- Inserm (FR)
- University of Würzburg (DE)
- Department of Endocrinology (R.L., J.B., X.B.), Institut National du Cancer Cortico-Medullo Tumeurs Endocrines, Cochin Hospital, Institut Cochin, Institut National de la Santé et de la Recherche Médicale Unité 1016, René Descartes University, Paris, F-75006 France
- LMU Klinikum (DE)
- John Radcliffe Hospital (GB)
- University of Florence (IT)
- University of Padua (IT)
- Familial Cancer Clinic (G.O.), I-35100 Padova, Italy
- Charité – Universitätsmedizin Berlin (DE)
- Trinity College Dublin (IE)
- University of Turin (IT)
- National Health Service (GB)
- Corresponding author
- Arlt, Wiebke
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-01-01
- Volume
- 98
- Issue
- 1
- Pages
- 161-171
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1967949880
- Cited by
- 154
- References
- 48
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 8 · 2023: 4 · 2022: 14 · 2021: 10 · 2020: 17 · 2019: 8 · 2018: 17 · 2017: 5 · 2016: 11 · 2015: 14 · 2014: 19 · 2013: 10
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by-nc)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Florence Research (University of Florence) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- National Institute for Health and Care Research (FP7/2007–2013, ACF-2010-09-004, NF-SI-0508-10356)
- European Commission (2007–2013, FP7 2007-2013, 259735, FP7/2007)
- Medical Research Council (FP7/20072013, G0801473)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- mitotane, adrenocortical carcinoma, CYP3A4 induction, 5α-reductase inhibition, steroidogenesis, 6β-hydroxycortisol, urinary steroid metabolites, adrenal insufficiency, male hypogonadism, glucocorticoid replacement therapy, androgen replacement, adjuvant therapy, finasteride
- MeSH terms
- Adolescent, Adrenal Cortex Neoplasms, Adult, Aged, Aged, 80 and over, Androgens, Enzyme Activation, Female, Glucocorticoids, Health Services Needs and Demand, Humans, Male, Middle Aged, Mitotane, 3-Oxo-5-alpha-Steroid 4-Dehydrogenase, Down-Regulation, Up-Regulation, Adrenocortical Carcinoma, Antineoplastic Agents, Hormonal, Hormone Replacement Therapy, Cytochrome P-450 CYP3A, Young Adult, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.